Hit early, hit hard! Integrated case-based management of CKD in T2DM

The,Doctor,Looks,At,The,Kidney,Hologram,,Checks,The,Test

Dr Alkesh Magan, Endocrinologist and Prof Feziwe Bisiwe, Nephrologist, present integrated case-based management of CKD in T2DM with evidence regarding Finerenone

Learning objectives

You will learn:

  • Benefits of early recognition of kidney disease in type 2 diabetes (T2DM) for improving cardiovascular outcomes
  • Reasons why albuminuria is both an important biomarker and a treatment target in patients with T2DM
  • Multifactorial drivers of chronic kidney disease (CKD) progression in T2DM and their implications for medical management
  • Clinical evidence regarding finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, and international guideline recommendations on its use for the treatment of CKD and T2DM.
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record 1 CPD point from the live webinar, invalidating any additional CPD points from the report.Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don't upload these yourself.

To access this module, please register or login: